Suppr超能文献

过氧化物酶体增殖物激活受体-γ激动剂治疗肝纤维化。

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

机构信息

Department of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, 200060, People's Republic of China.

Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, People's Republic of China.

出版信息

Drug Des Devel Ther. 2021 Jun 18;15:2619-2628. doi: 10.2147/DDDT.S310163. eCollection 2021.

Abstract

Liver fibrosis is a common link in the transformation of acute and chronic liver diseases to cirrhosis. It is of great clinical significance to study the factors associated with the induction of liver fibrosis and elucidate the method of reversal. Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear transcription factors that can be activated by peroxisome proliferators. PPARs play an important role in fibrosis of various organs, especially the liver, by regulating downstream targeted pathways, such as TGF-β, MAPKs, and NF-κB p65. In recent years, the development and screening of PPAR-γ ligands have become a focus of research. The PPAR-γ ligands include synthetic hypolipidemic and antidiabetic drugs. In addition, microRNAs, lncRNAs, circRNAs and nano new drugs have attracted research interest. In this paper, the research progress of PPAR-γ in the pathogenesis and treatment of liver fibrosis was discussed based on the relevant literature in recent years.

摘要

肝纤维化是急性和慢性肝病向肝硬化转化的共同途径。研究与肝纤维化诱导相关的因素并阐明逆转方法具有重要的临床意义。过氧化物酶体增殖物激活受体 (PPARs) 是一类可被过氧化物酶体增殖物激活的核转录因子。PPARs 通过调节下游靶向途径,如 TGF-β、MAPKs 和 NF-κB p65,在各种器官的纤维化中发挥重要作用,尤其是肝脏。近年来,PPAR-γ 配体的开发和筛选已成为研究热点。PPAR-γ 配体包括合成的降脂和抗糖尿病药物。此外,微小 RNA、长链非编码 RNA、环状 RNA 和纳米新药引起了研究兴趣。本文基于近年来的相关文献,讨论了 PPAR-γ 在肝纤维化发病机制和治疗中的研究进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验